Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database

References

• Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosisAm J Med19939466466508506892
   PubMed Web of Science ®Google Scholar
• NICEAlendronate etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal womenLondonNational Institute for Health and Care Excellence (NICE)2011 Available from: https://www.nice.org.uk/guidance/ta160Accessed July 2017
   Google Scholar
• NICEAlendronate etidronate, risedronate, raloxifene and strontium ranelate for the secondary prevention of osteoporotic fragility fractures in postmenopausal womenLondonNational Institute for Health and Care Excellence (NICE)2011 Available from: https://www.nice.org.uk/guidance/TA161Accessed July 2017
   Google Scholar
• DolanPTorgersonDJThe cost of treating osteoporotic fractures in the United Kingdom female populationOsteoporos Int19988661161710326069
   PubMed Web of Science ®Google Scholar
• BurgeRTWorleyDJohansenABhattacharyaSBoseUThe cost of osteoporotic fractures in the UK: projections for 2000–2020J Med Econ200141–45153
   Google Scholar
• CrandallCJNewberrySJDiamantAComparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic reviewAnn Intern Med20141611071172325199883
   PubMed Web of Science ®Google Scholar
• NakamuraTNakanoTItoMMOVER Study GroupClinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosisCalcif Tissue Int201393213714623644930
   PubMed Web of Science ®Google Scholar
• CurtisJRWestfallAOChengHSaagKGDelzellERisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reductionOsteoporos Int200920697397818946630
   PubMed Web of Science ®Google Scholar
• CadaretteSMKatzJNBrookhartMAStürmerTStedmanMRSolomonDHRelative effectiveness of osteoporosis drugs for preventing nonvertebral fractureAnn Intern Med2008148963764618458276
   PubMed Web of Science ®Google Scholar
• ReyesCPottegårdASchwarzPReal-life and RCT participants: alendronate users versus FITs’ trial eligibility criterionCalcif Tissue Int201699324324927099132
   PubMed Web of Science ®Google Scholar
• FeldsteinACWeyckerDNicholsGAEffectiveness of bisphosphonate therapy in a community settingBone200944115315918926939
   PubMed Web of Science ®Google Scholar
• BrankinEWalkerMLynchNThe impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databasesCurr Med Res Opin20062271249125616834823
   PubMed Web of Science ®Google Scholar
• Carbonell AbellaCGuañabens GayNRegadera AnechinaLMarín RivesJATaverna LlauradóEAyechu RedínMPADHEPORAnalysis of therapeutic compliance in women with osteoporosisReumatol Clin201175299304 Spanish [with English abstract]21925445
   PubMedGoogle Scholar
• KothawalaPBadamgaravERyuSMillerRMHalbertRJSystematic review and meta-analysis of real-world adherence to drug therapy for osteoporosisMayo Clin Proc200782121493150118053457
   PubMed Web of Science ®Google Scholar
• BlackDMReissTFNevittMCCauleyJKarpfDCummingsSRDesign of the fracture intervention trialOsteoporos Int19933Suppl 3S29S39
   Google Scholar
• RothwellPMExternal validity of randomised controlled trials: “to whom do the results of this trial apply?Lancet20053659453829315639683
   PubMed Web of Science ®Google Scholar
• HerrettEGallagherAMBhaskaranKData resource profile: clinical practice research datalink (CPRD)Int J Epidemiol201544382783626050254
   PubMed Web of Science ®Google Scholar
• HughesDEWrightKRUyHLBisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivoJ Bone Miner Res19951010147814878686503
   PubMed Web of Science ®Google Scholar
• PlotkinLIWeinsteinRSParfittAMRobersonPKManolagasSCBellidoTPrevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitoninJ Clin Invest1999104101363137410562298
   PubMed Web of Science ®Google Scholar
• MariePJAmmanPBoivinGReyCMechanisms of action and therapeutic potential of strontium in boneCalcif Tissue Int200169312112911683526
   PubMed Web of Science ®Google Scholar
• TurnerCHSatoMBryantHURaloxifene preserves bone strength and bone mass in ovariectomized ratsEndocrinology19941355200120057956922
   PubMed Web of Science ®Google Scholar
• AustinPCThe performance of different propensity-score methods for estimating relative risksJ Clin Epidemiol200861653754518471657
   PubMed Web of Science ®Google Scholar
• FineJPGrayRJA proportional hazards model for the subdistribution of a competing riskJ Am Stat Assoc199994446496509
   Web of Science ®Google Scholar
• ScruccaLSantucciAAversaFCompeting risk analysis using R: an easy guide for cliniciansBone Marrow Transplant200740438138717563735
   PubMed Web of Science ®Google Scholar
• RosenbaumPRObservational studyEverittBSDavidCEncyclopedia of Statistics in Behavioral Science LtdChichester, UKJohn Wiley and Sons200518091814
   Google Scholar
• KeeleLAn overview of rbounds: an R package for Rosenbaum bounds sensitivity analysis with matched dataColumbus, OH White Paper2010
   Google Scholar
• WellsGACranneyAPetersonJAlendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenCochrane Database Syst Rev20081CD001155
   Google Scholar
• WellsGCranneyAPetersonJRisedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenCochrane Database Syst Rev20081CD004523
   Google Scholar
• FreemantleNCooperCDiez-PerezAResults of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysisOsteoporos Int201324120921722832638
   PubMed Web of Science ®Google Scholar
• MeunierPJRouxCSeemanEThe effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosisN Engl J Med2004350545946814749454
   PubMed Web of Science ®Google Scholar
• ReginsterJYSeemanEDe VernejoulMCStrontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) studyJ Clin Endocrinol Metab20059052816282215728210
   PubMed Web of Science ®Google Scholar
• BlackDMThompsonDEBauerDCFracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research GroupJ Clin Endocrinol Metab200085114118412411095442
   PubMed Web of Science ®Google Scholar
• Strontium ranelate discontinuedDrug Ther Bull20175589394
   Google Scholar
• EttingerBBlackDMMitlakBHReduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) InvestigatorsJAMA1999282763764510517716
   PubMed Web of Science ®Google Scholar
• Prieto-AlhambraDJavaidMKJudgeAFracture risk before and after total hip replacement in patients with osteoarthritis: potential benefits of bisphosphonate useArthritis Rheum2011634992100121452321
   PubMed Web of Science ®Google Scholar
• Prieto-AlhambraDJavaidMKJudgeABisphosphonate use and risk of post-operative fracture among patients undergoing a total knee replacement for knee osteoarthritis: a propensity score analysisOsteoporos Int20112251555157120694456
   PubMed Web of Science ®Google Scholar
• Van StaaTPAbenhaimLCooperCZhangBLeufkensHGThe use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and resultsPharmacoepidemiol Drug Saf20009535936619025840
   PubMed Web of Science ®Google Scholar
• Pagès-CastellàACarbonell-AbellaCAvilésFFBurden of osteoporotic fractures in primary health care in Catalonia (Spain): a population-based studyBMC Musculoskelet Disord20121313798522639802
   PubMed Web of Science ®Google Scholar
• CurtisEMVan Der VeldeRMoonRJEpidemiology of fractures in the United Kingdom 1988-2012: variation with age, sex, geography, ethnicity and socioeconomic statusBone201687192626968752
   PubMed Web of Science ®Google Scholar
• Martinez-LagunaDSoria-CastroACarbonell-AbellaCValidation of fragility fractures in primary care electronic medical records: a population-based studyReumatol Clin Epub20171128
   Web of Science ®Google Scholar
• NormandSLSykoraKLiPMamdaniMRochonPAAndersonGMReaders guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confoundingBMJ200533074981021102315860831
   PubMed Web of Science ®Google Scholar
• Information System for Research in Primary Care Database www.sidiap.orgBarcelonaCatalan Health Institute2014 Available from: http://www.sidiap.org.
   Google Scholar
• Clinical Practice Research Datalink [www.cprd.com]LondonThe Medicines and Healthcare products Regulatory Agency2018 Available from: http://www.cprd.com
   Google Scholar